GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
In early 1987, he persuaded 11 Doobie alumni to join him for a concert to benefit veterans' causes. Answering the call were Tom Johnston, Pat Simmons, Jeff Baxter, John McFee, John Hartman, Michael Hossack, Chet McCracken, Michael McDonald, Cornelius Bumpus, Bobby LaKind and Tiran Porter, plus their long-time record producer and good friend, Ted Templeman. There were no surplus bass players as Weeks had other commitments. They soon discovered that tickets were in great demand, so the concert quickly evolved into a 12-city tour that began on May 21, 1987, in San Diego. The third concert, held at the Hollywood Bowl, was reportedly the venue's fastest sell-out since the Beatles had played there just over 20 years earlier. The band performed selections from every album using a wide variety of instrumentation that they could not have previously duplicated onstage without the expanded lineup. Baxter and McFee played pedal steel and violin, respectively, during "Black Water" and "Steamer Lane Breakdown". "Without You" featured four drummers and four lead guitarists. Producer Ted Templeman played percussion and LaKind sometimes played Knudsen's drum set while Knudsen went to the front of the stage to join the chorus. Templeman also played the drum set on "What a Fool Believes", as he did on the original hit record. The tour culminated (sans McDonald, LaKind, McFee and Knudsen) at the Glasnost-inspired July 4 "Peace Concert" in Moscow, with Bonnie Raitt, James Taylor and Santana sharing the bill.
=== Troponin === In both cardiac and skeletal muscles, muscular force production is controlled primarily by changes in the intracellular calcium concentration. In general, when calcium rises, the muscles contract and, when calcium falls, the muscles relax. Troponin, along with actin and tropomyosin, is the protein complex to which calcium binds to trigger the production of muscular force.
Talks quickly broke down, and final efforts in October to achieve a settlement floundered; the Smith government remained unwilling to accept the five principles of independence, and the British government argued it would settle for nothing less. On 11 November 1965 the Cabinet of Rhodesia issued a unilateral declaration of independence (UDI). The UDI was immediately denounced as an "act of rebellion against the Crown" in the United Kingdom, and Wilson promised that the illegal action would be short-lived. However, given its self-governing status Rhodesia had no longer been within the United Kingdom's direct sphere of influence for some time, and the façade of continued British rule was rendered a constitutional fiction by UDI. In light of these circumstances, Wilson quickly realised his ability to assert direct leverage over the incumbent Rhodesian government was limited. On 12 October 1965, the United Nations General Assembly had noted the repeated threats of the Rhodesian authorities "to declare unilaterally the independence of Southern Rhodesia, in order to perpetuate minority rule", and called upon Wilson to use all means at his disposal (including military force) to prevent the Rhodesian Front from asserting independence. After UDI was proclaimed, UN officials branded the Rhodesian government as an "illegal racist minority regime" and called on member states to voluntarily sever economic ties with Rhodesia, recommending sanctions on petroleum products and military hardware.
Venom is used as a trophic weapon by many predator species. The coevolution between predators and prey is the driving force of venom resistance, which has evolved multiple times throughout the animal kingdom. The coevolution between venomous predators and venom-resistant prey has been described as a chemical arms race. Predator/prey pairs are expected to coevolve over long periods of time. As the predator capitalizes on susceptible individuals, the surviving individuals are limited to those able to evade predation. Resistance typically increases over time as the predator becomes increasingly unable to subdue resistant prey. The cost of developing venom resistance is high for both predator and prey. The payoff for the cost of physiological resistance is an increased chance of survival for prey, but it allows predators to expand into underutilised trophic niches. The California ground squirrel has varying degrees of resistance to the venom of the Northern Pacific rattlesnake. The resistance involves toxin scavenging and depends on the population. Where rattlesnake populations are denser, squirrel resistance is higher. Rattlesnakes have responded locally by increasing the effectiveness of their venom. The kingsnakes of the Americas are constrictors that prey on many venomous snakes. They have evolved resistance which does not vary with age or exposure. They are immune to the venom of snakes in their immediate environment, like copperheads, cottonmouths, and North American rattlesnakes, but not to the venom of, for example, king cobras or black mambas.
== Pathophysiology == The pathophysiology of unstable angina is controversial. Previously, unstable angina was assumed to be angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm leading to myocardial ischemia. However, sensitive troponin assays reveal rise of cardiac troponin in the bloodstream with episodes of even mild myocardial ischemia. Since unstable angina is assumed to occur in the setting of acute myocardial ischemia without troponin release, the concept of unstable angina is being questioned with some calling for retiring the term altogether.
Sources: en.wikipedia.org
Restrictions on cash payment transactions: Transactions exceeding N5 million for individuals and N10 million for corporate bodies are to be made through a banking system, and any attempt at breaking up these transactions must be reported. Enhanced KYC requirements for agents and politically exposed persons; The act also states that all agents acting on behalf of customers must be fully identified and verified. It also established that the source of wealth of political persons must be investigated and identified.
The Second Collier Ministry was the 18th Ministry of the Government of Western Australia and was led by Labor Premier Philip Collier. It succeeded the Second Mitchell Ministry on 24 April 1933, following the defeat of the Nationalist government at the 1933 election on 8 April. The ministry was followed by the Willcock Ministry on 27 August 1936, a week after Collier resigned as Premier on the grounds of ill health and handed over to the Deputy Premier, John Willcock. The following ministers served until the reconstitution of the ministry on 26 March 1935:
Protriptyline acts by decreasing the reuptake of norepinephrine and to a lesser extent serotonin (5-HT) in the brain. Its affinity for the human norepinephrine transporter (NET) is 1.41 nM, 19.6 nM for the serotonin transporter and 2,100 nM for the dopamine transporter. TCAs act to change the balance of naturally occurring chemicals in the brain that regulate the transmission of nerve impulses between cells. Protriptyline increases the concentration of norepinephrine and serotonin (both chemicals that stimulate nerve cells) and, to a lesser extent, blocks the action of another brain chemical, acetylcholine. The therapeutic effects of protriptyline, like other antidepressants, appear slowly. Maximum benefit is often not evident for at least two weeks after starting the drug. Protriptyline is a TCA. It was thought that TCAs work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by neurons. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. TCAs are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the central nervous system via an indirect serotonergic route.
87Rb, 187Re, 176Lu, 232Th, and 238U have half-lives long enough that their decay is limited over geological time scales; 40K and 235U have shorter half-lives and are hence severely depleted, but are still long-lived enough to remain present in significant amount on Earth. The longest-lived isotope not proven to be primordial is 146Sm, which has a half-life of 9.20×107 years, followed by 244Pu (8.13×107 years) and 92Nb (3.47×107 years). 244Pu was reported to exist in nature as a primordial nuclide in 1971, but this detection could not be confirmed by further studies in 2012 and 2022. Taking into account that all these nuclides must exist for at least 4.58×109 years, 146Sm must survive 50 half-lives (and hence be reduced by 250 ≈ 1×1015), 244Pu must survive 57 (and be reduced by a factor of 257 ≈ 1×1017), and 92Nb must survive 130 (and be reduced by 2130 ≈ 1×1039). Mathematically, considering the likely initial abundances of these nuclides, primordial 146Sm and 244Pu should persist somewhere within the Earth today, even if they are not identifiable in the relatively minor portion of the Earth's crust available to human assays, while 92Nb and all shorter-lived nuclides should not. Nuclides such as 92Nb that were present in the primordial solar nebula but have long since decayed away completely are termed extinct radionuclides if they have no other means of being regenerated. As for 244Pu, calculations suggest that as of 2022, sensitivity limits were about one order of magnitude away from detecting it as a primordial nuclide.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.